nova red solution Search Results


horse red blood cells  (Innovative Research Inc)
90
Innovative Research Inc horse red blood cells
Horse Red Blood Cells, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/horse red blood cells/product/Innovative Research Inc
Average 90 stars, based on 1 article reviews
horse red blood cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nova red substrate solution  (Vector Laboratories)
96
Vector Laboratories nova red substrate solution
Nova Red Substrate Solution, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nova red substrate solution/product/Vector Laboratories
Average 96 stars, based on 1 article reviews
nova red substrate solution - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
human insulin solution novolin r  (Novo Nordisk)
90
Novo Nordisk human insulin solution novolin r
Human Insulin Solution Novolin R, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human insulin solution novolin r/product/Novo Nordisk
Average 90 stars, based on 1 article reviews
human insulin solution novolin r - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
solution comprised vector nova red chromogen  (Vector Laboratories)
86
Vector Laboratories solution comprised vector nova red chromogen
Solution Comprised Vector Nova Red Chromogen, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/solution comprised vector nova red chromogen/product/Vector Laboratories
Average 86 stars, based on 1 article reviews
solution comprised vector nova red chromogen - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
α-amylase, termamyl® 120 l  (Novo Nordisk)
90
Novo Nordisk α-amylase, termamyl® 120 l
α Amylase, Termamyl® 120 L, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α-amylase, termamyl® 120 l/product/Novo Nordisk
Average 90 stars, based on 1 article reviews
α-amylase, termamyl® 120 l - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
peelzym ii  (Novo Nordisk)
90
Novo Nordisk peelzym ii
Peelzym Ii, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peelzym ii/product/Novo Nordisk
Average 90 stars, based on 1 article reviews
peelzym ii - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
termamyl solution  (Novozymes limited)
90
Novozymes limited termamyl solution
Termamyl Solution, supplied by Novozymes limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/termamyl solution/product/Novozymes limited
Average 90 stars, based on 1 article reviews
termamyl solution - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
liraglutide victoza® ns6je85  (Novo Nordisk)
90
Novo Nordisk liraglutide victoza® ns6je85
Tirzepatide and <t>liraglutide</t> treatment led to robust weight reduction combined with AngII. Body weight changes during the treatment period in grams A , Mean ± SEM) and in percent B , and on the day of termination C . Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
Liraglutide Victoza® Ns6je85, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liraglutide victoza® ns6je85/product/Novo Nordisk
Average 90 stars, based on 1 article reviews
liraglutide victoza® ns6je85 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
betagan-levobunolol hydrochloride solution  (Allergan)
90
Allergan betagan-levobunolol hydrochloride solution
Tirzepatide and <t>liraglutide</t> treatment led to robust weight reduction combined with AngII. Body weight changes during the treatment period in grams A , Mean ± SEM) and in percent B , and on the day of termination C . Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
Betagan Levobunolol Hydrochloride Solution, supplied by Allergan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/betagan-levobunolol hydrochloride solution/product/Allergan
Average 90 stars, based on 1 article reviews
betagan-levobunolol hydrochloride solution - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
insulin solution  (Novo Nordisk)
90
Novo Nordisk insulin solution
Tirzepatide and <t>liraglutide</t> treatment led to robust weight reduction combined with AngII. Body weight changes during the treatment period in grams A , Mean ± SEM) and in percent B , and on the day of termination C . Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
Insulin Solution, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/insulin solution/product/Novo Nordisk
Average 90 stars, based on 1 article reviews
insulin solution - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
enzymatic solution ultrazym  (Novo Nordisk)
90
Novo Nordisk enzymatic solution ultrazym
Tirzepatide and <t>liraglutide</t> treatment led to robust weight reduction combined with AngII. Body weight changes during the treatment period in grams A , Mean ± SEM) and in percent B , and on the day of termination C . Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
Enzymatic Solution Ultrazym, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/enzymatic solution ultrazym/product/Novo Nordisk
Average 90 stars, based on 1 article reviews
enzymatic solution ultrazym - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nova red solution  (Vector Laboratories)
96
Vector Laboratories nova red solution
Tirzepatide and <t>liraglutide</t> treatment led to robust weight reduction combined with AngII. Body weight changes during the treatment period in grams A , Mean ± SEM) and in percent B , and on the day of termination C . Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
Nova Red Solution, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nova red solution/product/Vector Laboratories
Average 96 stars, based on 1 article reviews
nova red solution - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


Tirzepatide and liraglutide treatment led to robust weight reduction combined with AngII. Body weight changes during the treatment period in grams A , Mean ± SEM) and in percent B , and on the day of termination C . Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001

Journal: Cardiovascular Diabetology

Article Title: Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide

doi: 10.1186/s12933-025-02806-5

Figure Lengend Snippet: Tirzepatide and liraglutide treatment led to robust weight reduction combined with AngII. Body weight changes during the treatment period in grams A , Mean ± SEM) and in percent B , and on the day of termination C . Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001

Article Snippet: Based on the treatment, AngII-induced and sham-operated animals were separated into 3 groups: (i) vehicle groups (Sham/Veh n = 7 and AngII/Veh n = 15) received physiological saline intraperitoneally (i.p.) on a daily basis in an equivalent volume relative to the body weight. (ii) tirzepatide groups (Sham/TZP n = 8 and AngII/TZP n = 15) received tirzepatide (TZP, dissolved in physiological saline, BOC Sciences, London, UK) subcutaneously (s.c.) with a dose of 48 μg/kg/day [ ] (iii) liraglutide groups (Sham/Lira n = 7 and AngII/Lira n = 15) received liraglutide (Lira, (Victoza®, Solution for injection in 6 mg/ml pre-filled pen, NS6JE85, NOVO NORDISK, Denmark) via intraperitoneal (i.p.) injection with a 300 μg/kg/day dose [ ].

Techniques:

Tirzepatide and liraglutide preserved cardiac function. Functional parameters of the heart after one A and two weeks B of AngII infusion. Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, and ****P < 0.0001

Journal: Cardiovascular Diabetology

Article Title: Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide

doi: 10.1186/s12933-025-02806-5

Figure Lengend Snippet: Tirzepatide and liraglutide preserved cardiac function. Functional parameters of the heart after one A and two weeks B of AngII infusion. Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, and ****P < 0.0001

Article Snippet: Based on the treatment, AngII-induced and sham-operated animals were separated into 3 groups: (i) vehicle groups (Sham/Veh n = 7 and AngII/Veh n = 15) received physiological saline intraperitoneally (i.p.) on a daily basis in an equivalent volume relative to the body weight. (ii) tirzepatide groups (Sham/TZP n = 8 and AngII/TZP n = 15) received tirzepatide (TZP, dissolved in physiological saline, BOC Sciences, London, UK) subcutaneously (s.c.) with a dose of 48 μg/kg/day [ ] (iii) liraglutide groups (Sham/Lira n = 7 and AngII/Lira n = 15) received liraglutide (Lira, (Victoza®, Solution for injection in 6 mg/ml pre-filled pen, NS6JE85, NOVO NORDISK, Denmark) via intraperitoneal (i.p.) injection with a 300 μg/kg/day dose [ ].

Techniques: Functional Assay

Angiotensin II produced conduction and repolarization abnormalities, mitigated by tirzepatide and liraglutide. Representative electrocardiograms from lead II A and QRS width measured in lead III B Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05

Journal: Cardiovascular Diabetology

Article Title: Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide

doi: 10.1186/s12933-025-02806-5

Figure Lengend Snippet: Angiotensin II produced conduction and repolarization abnormalities, mitigated by tirzepatide and liraglutide. Representative electrocardiograms from lead II A and QRS width measured in lead III B Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05

Article Snippet: Based on the treatment, AngII-induced and sham-operated animals were separated into 3 groups: (i) vehicle groups (Sham/Veh n = 7 and AngII/Veh n = 15) received physiological saline intraperitoneally (i.p.) on a daily basis in an equivalent volume relative to the body weight. (ii) tirzepatide groups (Sham/TZP n = 8 and AngII/TZP n = 15) received tirzepatide (TZP, dissolved in physiological saline, BOC Sciences, London, UK) subcutaneously (s.c.) with a dose of 48 μg/kg/day [ ] (iii) liraglutide groups (Sham/Lira n = 7 and AngII/Lira n = 15) received liraglutide (Lira, (Victoza®, Solution for injection in 6 mg/ml pre-filled pen, NS6JE85, NOVO NORDISK, Denmark) via intraperitoneal (i.p.) injection with a 300 μg/kg/day dose [ ].

Techniques: Produced

Tirzepatide and liraglutide alleviate the fibrosis and hypertrophy caused by angiotensin II infusion. Representatives of Sirius red staining in the heart A show that AngII infusion led to higher fibrosis compared to the controls. Markers of fibrosis and hypertrophy B Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001

Journal: Cardiovascular Diabetology

Article Title: Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide

doi: 10.1186/s12933-025-02806-5

Figure Lengend Snippet: Tirzepatide and liraglutide alleviate the fibrosis and hypertrophy caused by angiotensin II infusion. Representatives of Sirius red staining in the heart A show that AngII infusion led to higher fibrosis compared to the controls. Markers of fibrosis and hypertrophy B Two-way ANOVA followed by Holm–Sidak post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001

Article Snippet: Based on the treatment, AngII-induced and sham-operated animals were separated into 3 groups: (i) vehicle groups (Sham/Veh n = 7 and AngII/Veh n = 15) received physiological saline intraperitoneally (i.p.) on a daily basis in an equivalent volume relative to the body weight. (ii) tirzepatide groups (Sham/TZP n = 8 and AngII/TZP n = 15) received tirzepatide (TZP, dissolved in physiological saline, BOC Sciences, London, UK) subcutaneously (s.c.) with a dose of 48 μg/kg/day [ ] (iii) liraglutide groups (Sham/Lira n = 7 and AngII/Lira n = 15) received liraglutide (Lira, (Victoza®, Solution for injection in 6 mg/ml pre-filled pen, NS6JE85, NOVO NORDISK, Denmark) via intraperitoneal (i.p.) injection with a 300 μg/kg/day dose [ ].

Techniques: Staining